Atara Biotherapeutics (ATRA) Stock Price, News & Analysis

Company Overview

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Key Stats

• Today's Range: $7.02 to $7.85
• 50-Day Range: $6.05 to $18.00
• 52-Week Range: $5.40 to $23.44
• Volume: 102,277 shs
• Average Volume: 173,394 shs
• Market Capitalization: $40.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.75
• Consensus Rating: Moderate Buy

Atara Biotherapeutics Stock Analysis - MarketRank™

Atara Biotherapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 140th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Atara Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Atara Biotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atara Biotherapeutics are expected to grow in the coming year, from ($10.39) to ($10.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atara Biotherapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atara Biotherapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.94% of the float of Atara Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Atara Biotherapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Atara Biotherapeutics has recently increased by 28.97%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atara Biotherapeutics does not currently pay a dividend.

Dividend Growth

Atara Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.87

Percentage of Shares Shorted

18.94% of the float of Atara Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Atara Biotherapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Atara Biotherapeutics has recently increased by 28.97%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: N/A

News Sentiment

Atara Biotherapeutics has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

Search Interest

Only 1 people have searched for ATRA on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Atara Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Atara Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.70% of the stock of Atara Biotherapeutics is held by insiders.

Percentage Held by Institutions

70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATRA Stock Analysis - Frequently Asked Questions

How have ATRA shares performed this year?

Atara Biotherapeutics' stock was trading at $13.31 at the start of the year. Since then, ATRA shares have decreased by 46.6% and is now trading at $7.11.
View the best growth stocks for 2025 here.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating the consensus estimate of ($3.77) by $0.84. The biotechnology company earned $40.19 million during the quarter, compared to analyst estimates of $23 million.

When did Atara Biotherapeutics' stock split?

Atara Biotherapeutics's stock reverse split before market open on Thursday, June 20th 2024. The 1-25 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' top institutional shareholders include Redmile Group LLC (7.67%), Citadel Advisors LLC (4.64%), Bank of America Corp DE (3.56%) and Geode Capital Management LLC (0.95%). Insiders that own company stock include Anhco Nguyen, Pascal Touchon, Eric J Hyllengren, Jill Henrich, Carol Giltner Gallagher, Jakob Dupont, Amar Murugan, William K Heiden and Utpal Koppikar.
View institutional ownership trends.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Atara Biotherapeutics investors own include Agenus (AGEN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Athersys (ATHX), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY) and FuelCell Energy (FCEL).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATRA
• CUSIP: N/A
• CIK: 1604464
• Web: www.atarabio.com
• Phone: (805) 623-4211
• Fax: N/A
• Employees: 330
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.75
• High Stock Price Target: $25.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +149.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($25.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-276,130,000.00
• Net Margins: -132.58%
• Pretax Margin: -132.56%
• Return on Equity: N/A
• Return on Assets: -90.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.59
• Quick Ratio: 0.50

Sales & Book Value

• Annual Sales: $8.57 million
• Price / Sales: 4.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($24.34) per share
• Price / Book: -0.29

Miscellaneous

• Outstanding Shares: 5,760,000
• Free Float: 5,547,000
• Market Cap: $40.95 million
• Optionable: Optionable
• Beta: 0.46